Phosphorylated heterodimers of ERBB2 TMD/JMD mutants and EGFR bind PLCG1

Stable Identifier
R-HSA-9665706
Type
Reaction [binding]
Species
Homo sapiens
Compartment
plasma membrane
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
Phosphorylated heterodimers of ERBB2 TMD/JMD mutants and EGFR bind PLCG1
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
Activation of downstream PLCG1 signaling was demonstrated for ERBB2 R678Q, through activating tyrosine phosphorylation on PLCG1 (Bose et al. 2013). It is assumed that the heterodimer of ERBB2 R678Q and EGFR, like the wild type ERBB2:EGFR heterodimer, binds PLCG1.
Literature References
PubMed ID Title Journal Year
23220880 Activating HER2 mutations in HER2 gene amplification negative breast cancer

Bose, R, Shen, W, Aronson, AB, Goel, N, Koboldt, DC, Li, S, Searleman, AC, Ma, CX, Ellis, MJ, Shen, D, Ding, L, Monsey, J, Mardis, ER, Kavuri, SM

Cancer Discov 2013
Participants
Input
Output
Participates
as an event of
Normal reaction
PLCG1 binds to p-ERBB2:p-EGFR (Homo sapiens)
Functional status

Gain of function of p-6Y-ERBB2 R678Q:EGF:p-6Y-EGFR [plasma membrane]

Normal Entity
Disease Entity
Status
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Orlic-Milacic, M  (2019-10-31)
Reviewed
Bose, R  (2019-10-25)
Kancha, RK  (2019-11-03)
Krishna, A  (2019-10-25)
Created
Orlic-Milacic, M  (2019-10-31)
Cite Us!